[Articles] Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial | ClinicLens

Duvakitug showed significant evidence for clinical remission versus placebo, with no safety concerns identified, in patients with moderately to severely active ulcerative colitis.

Medical Literature · Updated 2026-08-10

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.